City’s largest share sale in four years shows Beijing’s determination to push China’s EV technologies worldwide, analysts say ...

Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

SINGAPORE] Companies have been flocking to file applications for initial public offerings (IPOs) in Hong Kong amid ...

This digital payment services provider is likely to get a lift from China's initiatives to boost domestic consumption.

Hong Kong is calling for robotaxi operator Pony AI . The $6 billion Chinese company is exploring an offering in the city just ...

This week, CATL, a leading domestic lithium battery company, launched its Hong Kong IPO, heating up the lithium battery sector.

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.

Law firms may want to rethink the pivot from Hong Kong to the U.S., given Trump’s tariffs have made way for a potential thaw ...

(Reuters) -Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong initial public offering, according to a ...

As trade restrictions tighten across the U.S. and EU, and as global technology rivalries deepen, CATL's ambitions stretch ...

CATL has already reached the peak of the A-share market. The market fluctuations in the past two years and the competition from peers have caused some anxiety for the "Battery King," requiring it to ...